Two big announcements and no SP move?, page-9

Look at it realistically ‘h’, 15/3: New Agreement ... : tick, 15/3: Obj Rights to Sub categories: imo, neutral impact at the best, worst case scenario is that P&G see these sub categories as something that has no value to them, regardless of the fact that they may not ‘fit’ in with their new direction.

The ‘going it alone’ a big red flag, imo.

Could be viewed, possibly, by competitors, as tainted, that is, does not have marketable value to them, these sub-categories would also have the minus of its IP known to P&G, with ‘confidentially’ such a issue how does this impact its value to other entities?

Announcement: 9/3: S&P Indices Announces.... : Big minus, half hour or so later is the announcement of: Clinical Study reported as successful ...., this ,imo, is just ‘fluff’, am highly cynical of its ‘true’ value, imo, was purely issued to counter the negativity of the the former announcement.

Bottom line is this, imo, in regards to the ‘New Agreement’ signed, until resulting revenue is evident it is all hype.

This is the ‘reality’ hopeful, imo, why the sp is where it is. Only ‘really postive announcement’ is booming revenues once and for all, meanwhile, imo, this is a company that is on the ‘ropes’, no meaningful revenue by end of this year will see this company languishing below its current sp, imo.

Still no updates on surface hygiene! ... hmmnnn.